Agency Forms Undergoing Paperwork Reduction Act Review, 46677-46678 [2016-16872]
Download as PDF
<![CDATA[
46677
Federal Register / Vol. 81, No. 137 / Monday, July 18, 2016 / Notices
OMB approval is requested for three
years. Participation is based on previous
Emergency Epidemic Investigations.
There are no costs to respondents.
ESTIMATED ANNUALIZED BURDEN HOURS
Total
number of
responses per
respondent
Number of
respondents
Average
burden per
response
(in hours)
Total burden
hours
(in hours)
Type of respondent
Form name
Emergency Epidemic Investigation
Participants.
Emergency Epidemic Investigation
Data Collection Instruments.
12,000
1
30/60
6,000
Total ...........................................
...........................................................
........................
........................
........................
6,000
Jeffrey M. Zirger,
Acting Chief, Information Collection Review
Office, Office of Scientific Integrity, Office
of the Associate Director for Science, Office
of the Director, Centers for Disease Control
and Prevention.
[FR Doc. 2016–16882 Filed 7–15–16; 8:45 am]
BILLING CODE 4163–18–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
asabaliauskas on DSK3SPTVN1PROD with NOTICES
Statement of Organization, Functions,
and Delegations of Authority
Part C (Centers for Disease Control
and Prevention) of the Statement of
Organization, Functions, and
Delegations of Authority of the
Department of Health and Human
Services (45 FR 67772–76, dated
October 14, 1980, and corrected at 45 FR
69296, October 20, 1980, as amended
most recently at 81 FR 30307–30308,
dated May 16, 2016) is amended to
reflect the reorganization of the Office of
the Director, Centers for Disease Control
and Prevention.
Section C–B, Organization and
Functions, is hereby amended as
follows:
After the title and the mission and
function statements for the Office of the
Associate Director for Laboratory
Science and Safety (CAC) insert the
following:
Office of the Director (CAC1). (1)
Provides scientific, technical, and
managerial expertise and leadership in
the development and enhancement of
laboratory science and safety programs;
(2) oversees and monitors the
development, implementation, and
evaluation of the laboratory safety and
quality management programs across
CDC; (3) advises on policy,
partnerships, and issues management
matters; (4) advises on matters related to
internal and external public health
communications; (5) provides oversight
to ensure CDC compliance with
VerDate Sep<11>2014
17:52 Jul 15, 2016
Jkt 238001
regulations for select agents and toxins,
and the safe possession, use and transfer
of select agents and toxins; and (6) leads
responses to laboratory incidents and
emergencies.
Office of Laboratory Science (CACB).
(1) Provides high-level oversight and
coordination of laboratory quality and
safety training programs at all CDC
campuses; (2) develops agency-level
plans, policies, procedures and
guidelines for implementation of quality
management programs within Centers,
Institute, and Offices (CIOs); (3) assures
regulatory compliance and tracking for
CDC’s portfolio of laboratory developed
tests; and (4) provides oversight of the
catalog of laboratory safety training
activities and tracking agency-wide
progress and compliance with
laboratory safety training requirements.
Office of Laboratory Safety (CACC).
(1) Provides high-level oversight and
coordination of laboratory safety at all
CDC campuses; (2) develops and assures
effectiveness of agency-level plans,
policies, manuals and tools for
implementation of laboratory safety
standards; (3) assures regulatory
compliance for biological safety,
chemical safety, radiation safety and the
possession, use and transport of select
agents and toxins; and (4) provides
expertise and consultation for biological
safety, chemical safety and radiation
safety.
Sherri Berger,
Chief Operating Officer, Centers for Disease
Control and Prevention.
[FR Doc. 2016–16884 Filed 7–15–16; 8:45 am]
BILLING CODE 4160–18–P
PO 00000
Frm 00038
Fmt 4703
Sfmt 4703
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30-Day–16–16AVB]
Agency Forms Undergoing Paperwork
Reduction Act Review
The Centers for Disease Control and
Prevention (CDC) has submitted the
following information collection request
to the Office of Management and Budget
(OMB) for review and approval in
accordance with the Paperwork
Reduction Act of 1995. The notice for
the proposed information collection is
published to obtain comments from the
public and affected agencies.
Written comments and suggestions
from the public and affected agencies
concerning the proposed collection of
information are encouraged. Your
comments should address any of the
following: (a) Evaluate whether the
proposed collection of information is
necessary for the proper performance of
the functions of the agency, including
whether the information will have
practical utility; (b) Evaluate the
accuracy of the agencies estimate of the
burden of the proposed collection of
information, including the validity of
the methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected; (d) Minimize the burden of
the collection of information on those
who are to respond, including through
the use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and (e) Assess information
collection costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570 or
send an email to omb@cdc.gov. Written
comments and/or suggestions regarding
the items contained in this notice
E:\FR\FM\18JYN1.SGM
18JYN1
46678
Federal Register / Vol. 81, No. 137 / Monday, July 18, 2016 / Notices
should be directed to the Attention:
CDC Desk Officer, Office of Management
and Budget, Washington, DC 20503 or
by fax to (202) 395–5806. Written
comments should be received within 30
days of this notice.
Proposed Project
US Zika Pregnancy Registry—New—
National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID),
Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
In May 2015, the World Health
Organization reported the first local
transmission of Zika virus in the
Western Hemisphere, with
autochthonous cases identified in
Brazil. As of March 16, 2016, local
transmission has been identified in at
least 32 countries or territories in the
Americas. Further spread to other
countries in the region is likely. Local
vectorborne transmission of Zika virus
has not been documented in the 50 U.S.
states or the District of Columbia, but
has occurred in U.S. territories,
including in Puerto Rico, the U.S. Virgin
Islands, and American Samoa. However,
Zika virus infections have been reported
in travelers returning to the United
States from areas with active Zika virus
transmission. Zika virus infection also
has occurred through sexual
transmission, which may pose an
additional risk to non-travelling
pregnant women whose partners may
have traveled to areas at high risk for
Zika virus acquisition. With the ongoing
outbreak in the Americas, the number of
Zika virus disease cases among travelers
returning to the United States likely will
increase, and sexual transmission from
male travelers to their sex partners in
the United States will likely continue to
occur. In addition, mosquito-borne local
transmission may occur in states where
Aedes species mosquitoes are present.
In some Brazilian states where Zika
virus transmission has occurred, there
has been an increase in cases of infants
born with microcephaly. Zika virus
infections have been confirmed in
several infants with microcephaly and
in fetal losses in women infected during
pregnancy. In addition to microcephaly,
a range of other problems have been
detected among fetuses and infants
infected with Zika virus before birth,
such as absent or poorly developed
brain structures, defects of the eye,
hearing deficits, and impaired growth.
The Ministry of Health in Brazil, with
support from the Pan American Health
Organization (PAHO), the U.S. Centers
for Disease Control and Prevention
(CDC), and other partners, is
investigating the association between
Zika virus infection and microcephaly,
as well as other adverse pregnancy and
infant outcomes.
As part of the public health response
to the Zika virus disease outbreak, CDC
will conduct supplemental surveillance
of antenatal diagnostic testing and
clinical outcomes among pregnant
women with laboratory evidence of Zika
virus or unspecified flavivirus infection
and their infants through the U.S. Zika
Pregnancy Registry. It is anticipated that
the Registry will provide critical
information to direct CDC clinical
recommendations and public health
guidance and messages.
The objective of this Registry is to
monitor the frequency and types of
pregnancy and infant outcomes
following Zika virus infection during
pregnancy, so as to inform ongoing
response efforts for this Zika virus
disease outbreak, including
recommendations for clinical care,
planning for services for pregnant
women and infants affected by Zika
virus, and improved prevention of Zika
virus infections during pregnancy.
There are no costs to the respondents
other than their time. The total
estimated annual burden hours are
2,167.
ESTIMATED ANNUALIZED BURDEN HOURS
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hrs.)
Type of respondents
Form name
State, Territorial and Local Health Departments.
Maternal Health History Form ........................
100
10
30/60
Supplemental Imaging Form ..........................
Laboratory Results Form ...............................
Assessment at Delivery Form ........................
Infant Health Follow-Up Form ........................
100
100
100
100
10
10
10
30
10/60
15/60
30/60
15/60
Clinicians and Other Providers .......................
Jeffrey M. Zirger,
Acting Chief, Information Collection Review
Office, Office of Scientific Integrity, Office
of the Associate Director for Science, Office
of the Director, Centers for Disease Control
and Prevention.
[FR Doc. 2016–16872 Filed 7–15–16; 8:45 am]
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[Docket No. CDC–2016–0064; 60 Day–16–
0969]
asabaliauskas on DSK3SPTVN1PROD with NOTICES
BILLING CODE 4163–18–P
Proposed Data Collection Submitted
for Public Comment and
Recommendations
Centers for Disease Control and
Prevention (CDC), Department of Health
and Human Services (HHS).
ACTION: Notice with comment period.
AGENCY:
The Centers for Disease
Control and Prevention (CDC), as part of
its continuing efforts to reduce public
SUMMARY:
VerDate Sep<11>2014
17:52 Jul 15, 2016
Jkt 238001
PO 00000
Frm 00039
Fmt 4703
Sfmt 4703
burden and maximize the utility of
government information, invites the
general public and other Federal
agencies to take this opportunity to
comment on proposed and/or
continuing information collections, as
required by the Paperwork Reduction
Act of 1995. This notice invites
comment on ‘‘Monitoring Changes in
Attitudes and Practices among Family
Planning Providers and Clinics,’’ a
survey to assess dissemination and use
of guidance documents about the use of
contraceptives and the delivery of
quality family planning services.
Written comments must be
received on or before September 16,
2016.
DATES:
E:\FR\FM\18JYN1.SGM
18JYN1
]]>Agencies
[Federal Register Volume 81, Number 137 (Monday, July 18, 2016)]
[Notices]
[Pages 46677-46678]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2016-16872]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Centers for Disease Control and Prevention
[30-Day-16-16AVB]
Agency Forms Undergoing Paperwork Reduction Act Review
The Centers for Disease Control and Prevention (CDC) has submitted
the following information collection request to the Office of
Management and Budget (OMB) for review and approval in accordance with
the Paperwork Reduction Act of 1995. The notice for the proposed
information collection is published to obtain comments from the public
and affected agencies.
Written comments and suggestions from the public and affected
agencies concerning the proposed collection of information are
encouraged. Your comments should address any of the following: (a)
Evaluate whether the proposed collection of information is necessary
for the proper performance of the functions of the agency, including
whether the information will have practical utility; (b) Evaluate the
accuracy of the agencies estimate of the burden of the proposed
collection of information, including the validity of the methodology
and assumptions used; (c) Enhance the quality, utility, and clarity of
the information to be collected; (d) Minimize the burden of the
collection of information on those who are to respond, including
through the use of appropriate automated, electronic, mechanical, or
other technological collection techniques or other forms of information
technology, e.g., permitting electronic submission of responses; and
(e) Assess information collection costs.
To request additional information on the proposed project or to
obtain a copy of the information collection plan and instruments, call
(404) 639-7570 or send an email to omb@cdc.gov. Written comments and/or
suggestions regarding the items contained in this notice
[[Page 46678]]
should be directed to the Attention: CDC Desk Officer, Office of
Management and Budget, Washington, DC 20503 or by fax to (202) 395-
5806. Written comments should be received within 30 days of this
notice.
Proposed Project
US Zika Pregnancy Registry--New--National Center for Emerging and
Zoonotic Infectious Diseases (NCEZID), Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
In May 2015, the World Health Organization reported the first local
transmission of Zika virus in the Western Hemisphere, with
autochthonous cases identified in Brazil. As of March 16, 2016, local
transmission has been identified in at least 32 countries or
territories in the Americas. Further spread to other countries in the
region is likely. Local vectorborne transmission of Zika virus has not
been documented in the 50 U.S. states or the District of Columbia, but
has occurred in U.S. territories, including in Puerto Rico, the U.S.
Virgin Islands, and American Samoa. However, Zika virus infections have
been reported in travelers returning to the United States from areas
with active Zika virus transmission. Zika virus infection also has
occurred through sexual transmission, which may pose an additional risk
to non-travelling pregnant women whose partners may have traveled to
areas at high risk for Zika virus acquisition. With the ongoing
outbreak in the Americas, the number of Zika virus disease cases among
travelers returning to the United States likely will increase, and
sexual transmission from male travelers to their sex partners in the
United States will likely continue to occur. In addition, mosquito-
borne local transmission may occur in states where Aedes species
mosquitoes are present.
In some Brazilian states where Zika virus transmission has
occurred, there has been an increase in cases of infants born with
microcephaly. Zika virus infections have been confirmed in several
infants with microcephaly and in fetal losses in women infected during
pregnancy. In addition to microcephaly, a range of other problems have
been detected among fetuses and infants infected with Zika virus before
birth, such as absent or poorly developed brain structures, defects of
the eye, hearing deficits, and impaired growth. The Ministry of Health
in Brazil, with support from the Pan American Health Organization
(PAHO), the U.S. Centers for Disease Control and Prevention (CDC), and
other partners, is investigating the association between Zika virus
infection and microcephaly, as well as other adverse pregnancy and
infant outcomes.
As part of the public health response to the Zika virus disease
outbreak, CDC will conduct supplemental surveillance of antenatal
diagnostic testing and clinical outcomes among pregnant women with
laboratory evidence of Zika virus or unspecified flavivirus infection
and their infants through the U.S. Zika Pregnancy Registry. It is
anticipated that the Registry will provide critical information to
direct CDC clinical recommendations and public health guidance and
messages.
The objective of this Registry is to monitor the frequency and
types of pregnancy and infant outcomes following Zika virus infection
during pregnancy, so as to inform ongoing response efforts for this
Zika virus disease outbreak, including recommendations for clinical
care, planning for services for pregnant women and infants affected by
Zika virus, and improved prevention of Zika virus infections during
pregnancy.
There are no costs to the respondents other than their time. The
total estimated annual burden hours are 2,167.
Estimated Annualized Burden Hours
----------------------------------------------------------------------------------------------------------------
Number of Average burden
Type of respondents Form name Number of responses per per response
respondents respondent (in hrs.)
----------------------------------------------------------------------------------------------------------------
State, Territorial and Local Health Maternal Health History 100 10 30/60
Departments. Form.
Supplemental Imaging Form.. 100 10 10/60
Laboratory Results Form.... 100 10 15/60
Clinicians and Other Providers..... Assessment at Delivery Form 100 10 30/60
Infant Health Follow-Up 100 30 15/60
Form.
----------------------------------------------------------------------------------------------------------------
Jeffrey M. Zirger,
Acting Chief, Information Collection Review Office, Office of
Scientific Integrity, Office of the Associate Director for Science,
Office of the Director, Centers for Disease Control and Prevention.
[FR Doc. 2016-16872 Filed 7-15-16; 8:45 am]
BILLING CODE 4163-18-P
